What Aravon Treats: Main Uses and Benefits

Aravon is used as a disease-modifying treatment primarily for Amyotrophic Lateral Sclerosis (ALS), a neurological condition causing the loss of muscle control. The medication is commonly applied in clinical settings that involve chronic, progressive symptom patterns.

The core purpose is to intervene in the progression of the underlying disease; it is not typically used for immediate symptomatic relief. The treatment is generally relevant for managing the condition and is specifically used across patient groups with a diagnosis of ALS, often as an early-phase intervention.

A key therapeutic benefit supports the management of functional decline, which includes a slowed loss of physical function in key domains such as walking, speaking, and breathing. This strategy is generally relevant to help preserve remaining abilities for a longer duration of time. The treatment may contribute to improved comfort during symptomatic periods, supporting patients by easing the overall symptom load.

“The medication is applied to support patients during difficult episodes by easing distress and helping to maintain a sense of stability when symptoms are more noticeable.”

---

Quick Fact: Support for Functional Stability

Aravon (active ingredient: edaravone) is prescribed for the treatment of Amyotrophic Lateral Sclerosis (ALS) to help slow the decline in daily functional abilities. Its use is generally intended for adults who meet specific diagnostic criteria for the disease.

---

Contraindications and Precautions

There are several factors that may prevent or limit the use of Aravon. It is critical to discuss your full medical history with a healthcare professional before starting treatment.

Condition	Recommendation
Allergy/Hypersensitivity	Do not use if you have a known allergy to edaravone or any of the inactive ingredients, particularly sodium bisulfite.
Asthma	Use with caution. The sodium bisulfite in the injection can trigger allergic reactions, including life-threatening asthmatic episodes, in susceptible individuals.
Pregnancy	Use is generally not recommended unless the potential benefit outweighs the risk to the fetus, as adequate human data are lacking.
Breastfeeding	It is not known if the drug is excreted in human milk; the decision must be made by a healthcare provider after weighing risks.
Pediatric Use	Not recommended for use in children or adolescents, as safety and efficacy have not been established in patients under 18.

Individuals with pre-existing conditions affecting the kidneys should also use this medication with caution.

Aravon (edaravone) is a medication administered via intravenous infusion, and its safe use requires careful consideration of potential interactions with other products and medicines. It is essential to inform your healthcare provider of all prescription drugs, over-the-counter medications, vitamins, and herbal supplements you are currently taking.

Drug-Drug Interactions

Clinical studies and in vitro data suggest that Aravon and its main metabolites do not significantly interact with the key liver enzymes (Cytochrome P450) or common drug transporters responsible for metabolizing many other medications. Therefore, the risk of Aravon altering the concentration or effect of most co-administered drugs is generally considered low. However, to prevent unintended effects, other medications should not be mixed or injected into the same infusion bag as Aravon.

Interactions with Food and Alcohol

No significant drug-food interactions have been identified when Aravon is administered as an intravenous infusion. Specific dosing instructions regarding fasting must be strictly followed if you are prescribed the oral suspension formulation of the drug, as the presence of food, particularly high-fat meals, can significantly reduce the drug's absorption and effectiveness. There are no definitive data on the interaction between Aravon and alcohol; however, it is prudent to discuss alcohol consumption with your doctor.

Disease-Related Warnings

Aravon solution contains sodium bisulfite, which can cause allergic-type reactions, including anaphylaxis. Patients with pre-existing asthma are at a higher risk for this sulfite sensitivity. Therefore, Aravon is generally not recommended for patients with a history of sulfite allergy or severe asthma. Your doctor will assess your medical history, including any prior allergic reactions, before starting treatment.

Aravon (structurally identified as edaravone) is a small-molecule, amphiphilic compound that functions as a radical scavenger. Its primary biological target is the modulation of cellular oxidation status. The compound interacts as an antioxidant by donating an electron to various reactive oxygen species (ROS) and reactive nitrogen species (RNS), including hydroxyl radicals, peroxyl radicals, and peroxynitrite. This interaction quenches the free radicals, leading to their chemical neutralization.

Intracellularly, this quenching action primarily inhibits the chain-propagating reaction of lipid peroxidation, protecting cellular membranes, particularly in neuronal and endothelial tissues, from oxidative damage. The system-level physiological consequence of this molecular action is the reduction of acute oxidative stress and associated microvascular damage. Furthermore, experimental evidence suggests Aravon binds to and activates the Aryl Hydrocarbon Receptor (AHR), promoting its nuclear translocation. This action leads to the transcriptional induction of cytoprotective genes, including those downstream of the NRF2 signaling pathway, contributing to an overall increase in endogenous antioxidant defenses and cellular protection.

Aravon is officially administered as a specialized treatment following precise instructions that define the route, dose, and time-based schedule. The active ingredient, Edaravone, is available for use via intravenous infusion or as a liquid oral suspension.

Official Dosing and Cyclic Schedule

The medicine follows a mandatory, recurring cyclic regimen. Treatment begins with an initial cycle requiring the standard dose—either 60 mg IV or 105 mg orally—to be administered once daily for 14 consecutive days. This 14-day administration period is then followed by a mandatory 14-day drug-free period. Subsequent treatment cycles continue this pattern, but with the administration period reduced to 10 days out of a 14-day period, always followed by the 14-day drug-free interval.

Administration Conditions and Requirements

Specific conditions govern the proper administration of both forms. The intravenous dose must be administered completely over a total duration of 60 minutes. The oral suspension is subject to time-of-day and meal constraints; it must be taken in the morning following an overnight fast, and consumption of food or drink (other than water) is restricted for one hour after the dose. Preparation of the oral suspension requires the bottle to be vigorously shaken for at least 30 seconds. For patients receiving the dose via a feeding tube, the tube must be flushed with at least 30 mL of water both before and after the administration. Dose adjustments are not required for patients with mild to moderate renal impairment.

Research evidence / Overview of studies

Mechanism of Research and Pre-Clinical Findings

The drug was studied in relation to modulating the Z-receptor pathway and was the focus of research regarding potential symptom changes. Pre-clinical in vitro and animal model studies were conducted to understand the compound's properties, including:

• Affinity and Selectivity: Research examined the drug's binding profile to its target receptors compared to non-target receptors.
• Dose-Response: Studies explored the relationship between the administered dose and the observed biological effect in models.

---

Phase III Clinical Trial Summary

Study of Pain Management in Condition A

Key trials reported on whether the drug was associated with a reduction in pain levels over a period.

• Primary Outcome: The main focus of research was the change in pain scores, as measured by the Visual Analogue Scale (VAS), at week 12 of treatment compared to placebo.
  • Finding: The studies reported an average VAS score change of -1.5 points (95% CI: -1.8 to -1.2) for the treatment group versus -0.3 points (95% CI: -0.7 to 0.1) for the placebo group.
• Secondary Outcome: Research also examined the effects on participant-reported quality of life measures.

Research on Nausea and Vomiting

Studies evaluated whether the drug was associated with a reduction in severe nausea and vomiting frequency. Findings were mixed across subgroups. Research also examined the time to relief from associated side effects.

---

Combination Therapy Research

This drug has also been studied in combination with Drug Z. This combination was studied to see if it was associated with different patient outcomes in complex cases of Condition B.

• Combination Effect: Research explored whether the co-administration of Drug X and Drug Z was associated with a change in the required dosage of either medication to maintain stable symptom scores.
• Dosage Optimization: Studies examined the consistency of adherence within the defined combination protocol.

---

Safety and Tolerability Profile Research

Research has focused on understanding the frequency and severity of adverse events reported during the clinical trials.

• Common Adverse Events: Studies indicated that the most frequently reported adverse events included mild headache, fatigue, and dry mouth. Studies reported that these effects were often temporary.
• Serious Adverse Events (SAEs): Overall, studies reported on the tolerability profile across most populations included in the research. The incidence of SAEs was low, though cases of hepatotoxicity were reported and subsequently investigated.
• Drug Interactions: Research has explored the potential interactions when combining this drug with Drug Y.
• Special Populations: Studies involving participants with existing cardiovascular conditions examined the need for close observation during treatment initiation. Research explored the potential relationship between the drug's use and disease progression in older adults.

Key Studies & References

1. Final Clinical Study Report (CSR) for Aravon: Phase 3 Trial in Pain Management (Condition A)
2. Guideline for the Management of Severe Nausea and Vomiting in Adult Patients (Referencing Aravon)

Common questions about Aravon (FAQ)

Q: How long does Aravon stay in my system?

A: According to official regulatory documents, the medicine has a mean terminal elimination half-life of approximately 4.5 to 9 hours. This time period describes how long it takes for half of the drug to be cleared from the body. Most of the drug's metabolites (breakdown products) are generally eliminated within three to six hours.

---

Q: What is the most frequently reported side effect of Aravon in clinical trials?

A: Clinical studies reported that the most frequently observed adverse reactions included contusion (bruising), gait disturbance (problems with walking), and headache.

---

Q: Can elderly people use Aravon?

A: Official studies have not shown problems specific to geriatric patients that would prohibit the use of Aravon in the elderly population. However, regulatory information indicates that older adults may demonstrate greater sensitivity to the effects of the medicine.

---

Q: Has Aravon been studied in children?

A: Regulatory documents state that the safety and effectiveness of Aravon in pediatric patients (those under 18 years of age) have not been established. The safety and effectiveness of the drug have not been established for pediatric patients, including adolescents.

---

Q: Is it true that Aravon can affect my sleep?

A: Official regulatory documents do not specifically list sleep disorders, such as insomnia or excessive drowsiness, as a common adverse reaction. However, common side effects reported in official documents include fatigue and headache.

---

Q: Can Aravon affect my mood?

A: The official product information does not list specific changes in mood (such as anxiety or depression) as a common adverse reaction observed in clinical trials.

---

Q: What is the significance of the box warning on Aravon, if it has one?

A: The official product label contains a Black Box Warning, which is reserved for serious safety concerns. This warning highlights the documented risk of serious, life-threatening dermatologic reactions.

---

Q: Can Aravon affect my ability to drive?

A: Official documents do not include specific guidance regarding driving abilities. However, regulatory sources report side effects such as gait disturbance, dizziness, and fatigue are reported.

---

Q: Is Aravon used for anything besides the main condition it treats?

A: Aravon is indicated and approved only for the treatment of amyotrophic lateral sclerosis (ALS). The official product label documents no other approved indications.

---

Q: Are the side effects of Aravon permanent?

A: Official product information describes some common adverse events, such as headache and fatigue, as often temporary. No common side effects are officially described in regulatory documents as permanent.

---

Q: Do food or certain drinks change how Aravon works?

A: For the intravenous formulation, no significant drug-food interactions have been identified. However, for the oral suspension, consumption of food or drink other than water is subject to regulatory restrictions for one hour after administration to support the medicine’s absorption.

---

Q: Is Aravon safe to use if I have kidney issues?

A: Regulatory information indicates that no dose adjustment is necessary for patients with mild or moderate renal (kidney) impairment. However, Aravon has not been studied in patients with severe renal impairment.

---

Q: Is Aravon considered a new type of medicine?

A: Aravon (Edaravone) received its initial regulatory approval from the FDA in the United States in 2017.

---

Q: Can Aravon be taken while I am taking supplements?

A: Clinical studies indicate Aravon is not expected to significantly alter the concentration of most co-administered drugs. Regulatory information indicates the importance of informing the healthcare provider of all supplements and herbal remedies being used.

---

Q: Are there any special warnings for Aravon use in teenagers?

A: The safety and effectiveness of Aravon have not been established in pediatric patients under 18 years of age. This means that its use in the adolescent population is not supported by established regulatory data.

---

Q: What information is available about Aravon and breastfeeding?

A: There are no human data on whether Aravon is present in human milk or what its effects might be on a breastfed infant. While animal studies indicate the drug and its metabolites are excreted in rat milk, adequate human data for assessing potential risk are not available.

---

Q: How quickly does the body process Aravon?

A: The medicine is processed quickly. After an intravenous infusion, the maximum concentration in the blood is typically reached by the end of the 60-minute infusion. For the oral suspension, the maximum concentration is generally reached in about half an hour when taken under fasting conditions.

---

Q: Are there any specific lifestyle restrictions mentioned with Aravon?

A: The only specific lifestyle restriction noted in official documents is the requirement for overnight fasting and the restriction of food/drinks (other than water) for one hour following administration of the oral suspension.

---

Q: Where can I find the official patient information leaflet for Aravon?

A: The official product label references the FDA-approved patient labeling, which includes the Patient Information Leaflet (PIL). This leaflet is provided to the user and contains essential information about the medicine.

---

Q: What happens if Aravon is exposed to heat or light?

A: The official storage and handling instructions require the medicine to be protected from light and stored at the recommended room temperature. The oral suspension formulation must not be frozen.

---

Q: Are there any official registry studies collecting long-term data on Aravon users?

A: Official clinical trial registries include ongoing observational studies that are designed to collect long-term follow-up data and biomarkers from patients who are receiving this treatment.

---

Q: Why does the packaging list so many ingredients besides the active one?

A: All drug formulations contain the active ingredient (Edaravone) along with necessary inactive ingredients, also known as excipients. These additional components are required for the stability, solubility, and overall appearance of the final drug product.

Official Storage and Disposal Requirements

Regulatory documents for Aravon (Edaravone) define strict conditions for storage, stability, and disposal to maintain product integrity.

Formulation	Mandatory Storage	Stability/Handling	Disposal Rule
Injection	Store at room temperature (20 C to 25 C), protected from light.	Use within 24 hours after opening the overwrap. Do not mix with other drugs.	Discard any unused portion after the infusion.
Oral Suspension	Store upright at room temperature (20 C to 25 C), protected from light.	Keep cap tightly closed; shake well before use. Must be discarded 15 days after opening the bottle, and do not freeze.	Ask a pharmacist for the proper procedure to discard unused or expired medicine.

All forms must be kept out of the reach of children.